Comparison between paricalcitol versus cinacalcet therapy in the management of secondary hyperparathyroidism among prevalent hemodialysis patients
Introduction: Secondary hyperparathyroidism (SHPT) is one of the components of chronic kidney disease–mineral bone disorder (CKD-MBD) with significant contribution to the morbidity and mortality among prevalent hemodialysis (HD) patients. Objectives: This multi-centric experience study aims to compa...
Guardado en:
Autores principales: | Maha A. Behairy, Osama Mahmoud, Ayman Rabie Ibrahim, Aber H. Baki |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Society of Diabetic Nephropathy Prevention
2022
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8a4ebf413edf4aa9a895d6a4a4301004 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A comparative study on the effect of calcitriol and cinacalcet on hyperparathyroidism in hemodialysis patients; a double-blinded randomized clinical trial
por: Saeed Mardani, et al.
Publicado: (2022) -
A single-centre retrospective analysis of cinacalcet therapy in primary hyperparathyroidism
por: Daniel Bell, et al.
Publicado: (2021) -
Oral versus intramuscular cholecalciferol replacement in hemodialysis patients with vitamin D deficiency
por: Maha A. Behairy, et al.
Publicado: (2022) -
Bacteraemia by Achromobacter denitrificans in Hemodialysis
por: Venice Chavez-Valencia, et al.
Publicado: (2021) -
Acute vision loss on hemodialysis: Mönckeberg arteriosclerosis
por: Álvaro Pérez Fernández, et al.
Publicado: (2021)